Every 10-Q that Curis Inc (CRIS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.
Curis, Inc. is a biotechnology company developing emavusertib for hematologic cancers, with ongoing combination trials in relapsed/refractory PCNSL and CLL and substantially complete AML studies. Emavusertib holds multiple Orphan Drug Designations in the U.S. and EU.
For the six months ended June 30, 2026, Curis reported a net loss of $32.8 million and no revenue, versus $5.1 million of royalty revenue a year earlier, reflecting the 2025 sale of Erivedge royalties. R&D expense fell 18% to $13.2 million, while G&A rose 10% to $8.3 million, partly from the January 2026 PIPE financing. A $11.5 million non‑cash loss from warrant remeasurement drove other expense.
Cash and cash equivalents were $5.1 million and total assets $19.0 million at June 30, 2026. After an August 2026 equity offering expected to add about $4.8 million, management believes liquidity funds operations only into the fourth quarter of 2026 and discloses substantial doubt about continuing as a going concern without additional capital.
Curis, Inc. reported a net loss of $24.2 million for the three months ended March 31, 2026, more than double the prior-year period, as it transitions to being fully dependent on its IRAK4/FLT3 inhibitor emavusertib. Revenue fell to $0 from $2.4 million after the 2025 sale of Erivedge royalty rights. Research and development expenses declined 24% to $6.4 million, while general and administrative costs rose 27% to $5.1 million, driven largely by the January 2026 PIPE financing.
Curis ended the quarter with $15.0 million in cash and cash equivalents and used $9.0 million of cash in operations. The company explicitly states there is “substantial doubt” about its ability to continue as a going concern within one year without substantial additional capital, citing an accumulated deficit of about $1.3 billion and ongoing operating losses. Management plans to seek more financing and strategic options while focusing development on emavusertib in PCNSL and CLL.
Curis, Inc. filed its Q3 2025 10-Q reporting continued operating losses and tight liquidity. Net revenues were $3.176 million for the quarter, with a net loss of $7.729 million and net loss per share of $0.49. For the nine months, net revenues were $8.305 million and net loss totaled $26.938 million.
Cash and cash equivalents were $9.051 million as of September 30, 2025, and management disclosed conditions that raise substantial doubt about the company’s ability to continue as a going concern. Operating cash use was $20.830 million for the nine months.
Curis completed financings in March 2025 and July 2025, issuing common stock, pre‑funded warrants, and common warrants, with combined net proceeds of approximately $14.9 million. Total liabilities were $42.332 million, including $28.631 million related to the sale of future Erivedge royalties.
Subsequent event: on November 6, 2025, Curis sold its interest in Curis Royalty LLC to an Oberland affiliate for $2.5 million and obtained a release of the royalty‑related liability; Curis will no longer receive Erivedge collaboration revenues and expects to record a gain in Q4 2025.
Curis, Inc. (CRIS) – Q2 2025 Form 10-Q highlights
- Revenue: Erivedge royalties rose 8% YoY to $2.7 m for the quarter and 11% to $5.1 m for H1 2025.
- Costs: R&D cut 22% YoY to $16.0 m; G&A down 22% to $7.5 m. Total operating expenses fell 21% to $23.5 m.
- Losses: Q2 net loss $8.6 m (-27% YoY); H1 loss $19.2 m (-19% YoY). Basic EPS -$0.68 vs -$2.03.
- Cash position: Cash & cash equivalents declined to $10.1 m (vs $20.0 m YE-24) after $15.3 m H1 operating cash burn.
- Going-concern: Management warns cash runway extends only into Q1 2026; “substantial doubt” exists without new financing.
- Balance sheet: Stockholders’ deficit widened to $14.0 m; royalty-backed liability $30.2 m outstanding.
- Equity raises: March 2025 offerings net $8.8 m; July 2025 follow-on added ~$6 m post-quarter. Authorized shares doubled to 68.3 m; outstanding shares 12.5 m at 8/1/25.
- Pipeline: Lead IRAK4 inhibitor emavusertib in three clinical studies; received Orphan Drug status in AML, MDS & PCNSL. FDA & EMA meetings support accelerated paths.
- Risks: Single-asset dependence, Nasdaq listing deficiency, need for >$50 m additional capital, competitive and patent risks.
Outlook: Curis must secure near-term funding or a strategic partnership to continue emavusertib trials and satisfy royalty debt obligations.